[5]Han S,Iglay K,Davies MJ,et al.Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens:a meta-analysis[J].Curr Med Res Opin.2012,28(6):969-...
[5]Han S,Iglay K,Davies MJ,et al.Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens:a meta-analysis[J].Curr Med Res Opin.2012,28(6):969-77.DOI:10.1185/03007995.2012.684045. [6]Osterberg L,Blaschke T.Adheren...
[14]Han S,Iglay K,Davies MJ,et al.Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens:a meta-analysis[J].Curr Med Res Opin.2012,28(6):969-77.DOI:10.1185/03007995.2012.684045. [15]Osterberg L,Blaschke T.Adher...
[16]. Han S, Iglay K, Davies MJ,et al. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens:a meta-analysis[J]. Curr Med Res Opin, 2012, ...
共识建议SGLT2i联合二甲双胍治疗的适用人群包括以下七类患者(表1): 新诊断T2DM患者 二甲双胍或SGLT2i单药治疗不达标的患者 其他种类降糖药单药治疗不达标的患者 T2DM患者合并动脉粥样硬化性心血管疾病(ASCVD)或其高危因素 T2DM患者合并HF T2DM合并慢性肾脏病(CKD)或糖尿病肾脏病(DKD)患者 ...
共识建议SGLT2i联合二甲双胍治疗的适用人群包括以下七类患者(表1): 新诊断T2DM患者 二甲双胍或SGLT2i单药治疗不达标的患者 其他种类降糖药单药治疗不达标的患者 T2DM患者合并动脉粥样硬化性心血管疾病(ASCVD)或其高危因素 T2DM患者合并HF T2DM合并慢性肾脏病(CKD)或糖尿病肾脏病(DKD)患者 ...
(such as ketosis and genitourinary infection). The effect on adolescent patients remain further validated. This review summarizes several evidence of medication on type 1 diabetes by SGLT-2i derivatives, which could provide the powerful suggestions for clinicians.[Key words] SGLT-2i; Type 1 ...
Developed by Sanofi and Lexicon Pharmaceuticals, Inc., sotagliflozin has the potential to be the first oral antidiabetic drug approved in the United States together with insulin therapy to improve glycemic control in adults with T1D. Sotagliflozin is an investigational oral dual SGLT1 and SGL...
SGLT1 受体存在于大脑皮层的锥 体细胞,浦肯野小脑细胞,海马锥体细胞,颗粒细胞 以及下丘脑腹内侧核的胶质细胞. 而 SGLT2 在大 脑中的表达低于 SGLT1,主要存在于血脑屏障的微 血管中,也存在于杏仁核,下丘脑,中脑导水管周围 灰质和孤束核中[2] . 上述区域已经被证实负责学 习,食物摄入,能量和葡萄糖稳态的...
h-TTR2 (11.8)1 (2.6)N/A Medicationn(%) Beta-blocker7 (41.2)17 (42.5)0.790 MRA11 (64.7)8 (20.0)0.001 RAAS blockage ACE-I2 (11.8)5 (12.5)0.999 ARB7 (41.2)17 (42.5)0.926 ARNI2 (11.8)00.085 Loop diuretic13 (76....